704870-54-2

Upstream product

• 162465-44-3 methyl (2R)-2-[(tert-butoxycarbonyl)amino]-3-(3-chloro-4-methoxyphenyl)propanoate 
• 478183-57-2 (2R)-2-[(tert-butoxycarbonyl)amino]-3-(3-chloro-4-hydroxyphenyl)propanoic acid 
• 556-02-5 tyrosine 

Downstream Products

• 905309-57-1 methyl (2R)-2-(acryloylamino)-3-(3-chloro-4-methoxyphenyl)propanoate 
• 905309-72-0 (3S,10R,16S)-16-[(2Z)-2-benzylidene-4-phenylbut-3-ynyl]-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone 
• 905309-77-5 (1S,3Z)-1-allyl-4-iodo-4-phenylbut-3-enyl (2S)-2-({3-[(N-acryloyl-3-chloro-O-methyl-D-tyrosyl)amino]-2,2-dimethylpropanoyl}oxy)-4-methylpentanoate 
• 905309-82-2 (1R,3Z)-1-allyl-4-iodo-4-phenylbut-3-enyl (2S)-2-({3-[(N-acryloyl-3-chloro-O-methyl-D-tyrosyl)amino]-2,2-dimethylpropanoyl}oxy)-4-methylpentanoate 
• 905309-76-4 (1S,3Z)-1-allyl-3-bromo-4-phenylbut-3-enyl (2S)-2-({3-[(N-acryloyl-3-chloro-O-methyl-D-tyrosyl)amino]-2,2-dimethylpropanoyl}oxy)-4-methylpentanoate 
• 905309-75-3 (3S,10R,16S)-10-(3-chloro-4-methoxybenzyl)-16-[(2Z)-3-iodo-3-phenylprop-2-enyl]-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone 
• 905309-81-1 (3S,10R,16R)-10-(3-chloro-4-methoxybenzyl)-16-[(2Z)-3-iodo-3-phenylprop-2-enyl]-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone 
• 905309-74-2 (3S,10R,16S)-16-[(2Z)-2-bromo-3-phenylprop-2-enyl]-10-(3-chloro-4-methoxybenzyl)-3-isobutyl-6,6-dimethyl-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone 
• 905309-67-3 allyl (2S)-2-({3-[(N-acryloyl-3-chloro-O-methyl-D-tyrosyl)amino]-2,2-dimethylpropanoyl}oxy)-4-methylpentanoate 
• 905309-58-2 (2R)-2-(acryloylamino)-3-(3-chloro-4-methoxyphenyl)propanoic acid 

Relevant academic research and scientific papers

Total synthesis of cryptophycin analogues via a scaffold approach

Allylation of in situ generated β,γ-unsaturated aldehydes affords rapid access to vinyl halide analogues of fragment A of the cryptophycins. Three scaffolds are prepared in gram quantities by a ring-closing metathesis approach. Derivatization via a variety of cross-coupling protocols is possible, which affords novel analogues of these potent antimitotic agents.